SRPT

Sarepta Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-02

Figures on this page computed 2026-11-08 12:48 UTC

Last close

18.99USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-02

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-02
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
-32.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
-14.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
0.91Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.38 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.63x

1.75x

0.88x

1.20x

0.22x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-02

Sales2.63x
Its own average over 10 years, 836.0M.
Profit1.75x
Its own average over 10 years, -408.5M.
Free cash flow0.88x
Its own average over 10 years, -350.1M.
Debt1.20x
Its own average over 9 years, 865.5M.
Price0.22x
Its own average over 11 years, 88. Market data, 2026-11-04

Sales is furthest from its own average, at 2.63 times.

Sales is 2.63 times its own 10-year average; Profit is 1.75 times its own 10-year average; Free cash flow is 0.88 times its own 10-year average; Debt is 1.20 times its own 9-year average; Price is 0.22 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-02

Sales against its own 10-year average2.63
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
The filing itself
Profit against its own 10-year average1.75
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.88
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
The filing itself
Debt against its own 9-year average1.20
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
The filing itself
Price against its own 11-year average0.22Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD